• BIBP 3226 trifluoroacetate: Decoding the Adipose-Neural Axis

  2026-06-11

  Explore how BIBP 3226 trifluoroacetate empowers advanced cardiac arrhythmia research by targeting the neuropeptide Y Y1 and NPFF pathways. This article uniquely connects molecular pharmacology with breakthroughs in the adipose-neural axis, offering new insights for translational cardiovascular studies.

• PA-824 (A1736): Data-Driven Solutions for TB Research Challe

  2026-06-11

  This article provides practical, evidence-based guidance for biomedical researchers using PA-824 (SKU A1736) in tuberculosis research workflows. Drawing on real laboratory scenarios, it demonstrates how this bicyclic nitroimidazole derivative delivers reproducible, high-sensitivity results as a Mycobacterium tuberculosis inhibitor. By integrating protocol advice and product selection strategies, it helps scientists leverage PA-824 for robust, cost-effective experimentation.

• WNT5a/GSK3/β-Catenin Axis Controls FAP Adipogenesis in Muscl

  2026-06-10

  This study identifies the WNT5a/GSK3/β-catenin signaling pathway as a central regulator of adipogenic differentiation in skeletal muscle fibro/adipogenic progenitors (FAPs). By integrating multi-omic and pharmacological approaches, the research reveals new mechanisms controlling intramuscular fat accumulation and highlights potential strategies for modulating muscle degeneration.

• Benzyl Quinolone Carboxylic Acid: Precision in M1 Receptor M

  2026-06-10

  Benzyl Quinolone Carboxylic Acid (BQCA) unlocks selective, robust enhancement of M1 muscarinic acetylcholine receptor signaling—empowering reproducible cognitive and Alzheimer’s disease research. Explore protocol advances, troubleshooting, and workflow optimizations built on the latest mechanistic breakthroughs.

• H3K18 Lactylation in Microglia: A Protective Axis in ICH-Ind

  2026-06-09

  This study identifies lactate-derived H3K18 histone lactylation in microglia as a key endogenous neuroprotective mechanism regulating white matter injury (WMI) and cognitive function after intracerebral hemorrhage (ICH) in mice. The findings highlight the differential effects of metabolic (oxamate-mediated) and epigenetic (p300/CBP-mediated) inhibition on myelin repair, providing new targets for post-ICH brain recovery.

• PAD4-IN-2 TFA: Redefining Tumor-Selective PAD4 Inhibition

  2026-06-09

  Explore the mechanistic innovation and translational impact of PAD4-IN-2 TFA—a meta-phenylboronic acid-modified, tumor-targeted PAD4 inhibitor. This thought-leadership article blends the latest mechanistic insights with actionable strategic guidance for translational oncology researchers, illuminating how PAD4-IN-2 TFA advances the field beyond conventional PAD4 inhibition approaches.

• FOXM1–Estrogen Receptor Networks in Female Lung Adenocarcino

  2026-06-08

  This study establishes a mechanistic link between the transcription factor FOXM1, estrogen receptor signaling, and non-coding RNA networks in female lung adenocarcinoma (LUAD). By integrating large-scale transcriptomics and functional validation, the research identifies a novel ceRNA regulatory axis with implications for prognosis and immunotherapy responsiveness in LUAD.

• MAZ-BCKDK-G6PD Axis Drives Metabolic Reprogramming in TNBC

  2026-06-08

  This study uncovers a metabolic regulatory pathway in triple-negative breast cancer (TNBC), showing that MAZ-driven BCKDK upregulation stabilizes G6PD, thereby promoting glucose metabolism and tumor growth. These insights highlight the MAZ/BCKDK/G6PD axis as a promising therapeutic target and provide mechanistic clarity for metabolic interventions in aggressive breast cancers.

• Differential Mechanisms of Chuanxiong Cortex and Pith in CHD

  2026-06-07

  This study leverages SPME-GC×GC-MS and network pharmacology to dissect the unique bioactive profiles of Ligusticum chuanxiong rhizome cortex and pith in coronary heart disease (CHD) models. The findings highlight distinct volatile compound distributions and molecular targets, with Fenipentol (1-Phenyl-1-pentanol) emerging as a key cortex-derived modulator—offering new insights for targeted cardiovascular and gastrointestinal research.

• Native Protein Gel Electrophoresis: Precision and Innovation

  2026-06-06

  Explore how the Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit enables high-resolution native protein gel electrophoresis, preserving protein activity and structure for advanced biochemical research. Discover unique scientific insights and practical guidance that go beyond standard protocols.

• Vorinostat (SAHA): Advancing Translational Oncology via Epig

  2026-06-05

  This article delivers a mechanistic and strategic blueprint for translational researchers leveraging Vorinostat (SAHA) in oncology. Integrating evidence from in vitro evaluations, apoptosis metrics, and real-world assay challenges, it advances the discussion beyond standard product summaries—focusing on actionable guidance for experimental design, protocol optimization, and the translational bridge to clinical impact.

• Gut-Brain Cholinergic Pathways in B. fragilis Antiseizure Ef

  2026-06-05

  Jia et al. reveal a mechanistic link between gut microbiota and seizure suppression, demonstrating that Bacteroides fragilis activates gut-brain cholinergic signaling to mediate antiseizure effects. Their translational approach integrates animal models with clinical validation, offering new perspectives for microbiota-targeted epilepsy therapies.

• Bufalin-CRISPR Nanomedicine Induces Pyroptosis for CRC Immun

  2026-06-04

  A recent study introduces a calcium lactate nanoparticle system co-delivering bufalin and CRISPR/Cas9 to target colorectal cancer. This approach synergistically induces pyroptosis and macrophage M1 polarization, enhancing local and systemic antitumor immunity and offering a new strategy against therapy resistance.

• Nilotinib (AMN-107): Precision Solutions for Kinase Assays

  2026-06-04

  This article guides biomedical researchers through common challenges in kinase pathway assays and immunomodulation studies, demonstrating how Nilotinib (AMN-107, SKU A8232) delivers reproducible, quantitative results. Scenario-driven Q&A blocks offer evidence-backed insights and practical workflow recommendations for cell viability, proliferation, and cytotoxicity analyses.

• Synergistic Effects of SGI-1027 and Everolimus in Renal Canc

  2026-06-03

  This study uncovers the novel cytotoxic activity of SGI-1027, a DNA methyltransferase inhibitor, in inducing methuosis and enhancing apoptosis and pyroptosis in renal cancer cells. The combination of SGI-1027 with everolimus demonstrates potent anti-tumor effects and offers a promising strategy for overcoming drug resistance in advanced renal cell carcinoma.

16265 records 1/1085 page Next 12345 下5页 Last page